Controllable self-replicating RNA vaccine delivered intradermally elicits cellular immunity – preprint manuscript posted
BALTIMORE, September 7, 2022 — Elixirgen Therapeutics, Inc., a Baltimore-based, clinical-stage biotechnology company focused on the discovery, development, and commercialization of therapies using its controllable srRNA platform, announced today that it has posted a manuscript titled “Controllable self-replicating RNA vaccine delivered intradermally elicits cellular immunity” on the bioRxiv.org preprint server. The link to the preprint […]